Dr. Devorah Segal, M.D., PH.D.
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Icahn School of Medicine at Mount Sinai (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 24
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Icahn School of Medicine at Mount Sinai
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
NY license 278359
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- NYU Langone Hospitals New York, NY
Medical groups
- New York University (6,134 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 24
- Services billed
- 41
- Patients’ average age
- 55
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clonazepam Other prescribers in New York, NY | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $3,230 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $3,230 |
|---|
| Consulting Fee | $3,100 |
|---|---|
| Food and Beverage | $130 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Jul 23, 2025 | Consulting Fee STRENSIQ · Rare Disease | $1,240 |
| Alexion Pharmaceuticals, Inc. May 8, 2025 | Consulting Fee KOSELUGO · Oncology | $930 |
| Alexion Pharmaceuticals, Inc. Dec 4, 2025 | Consulting Fee KOSELUGO · Oncology | $930 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $338,320 in research payments for these studies, mostly to the institutions running them.
- A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT03771898 - Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT02412787
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.